dc.description |
Department of Internal
Medicine, Cardiology, Nicolae Testemitanu State University of Medicine and Pharmacy,
Chisinau, Republic of Moldova, The 8th International Medical Congress for Students and Young Doctors, September 24-26, 2020 |
en_US |
dc.description.abstract |
Background. Invasive pulmonary aspergillosis is a severe fungal infection with a high
mortality rate. Diagnosis is challenging due to the non-specific nature of symptoms. Allergic
bronchopulmonary aspergillosis (ABPA) complicated with pulmonary thromboembolism
(PTE) is rare. This report describes a patient who was diagnosed with ABPA and soon
developed PTE, for which he was admitted to our department. In the recent years, ABPA has
become more and more common clinically, especially in patients with cystic fibrosis or asthma,
which can lead to irreversible bronchiectasis, pulmonary fibrosis, and even death. The common
complications of ABPA include recurrent exacerbations, bronchiectasis, and acute respiratory failure. It is generally believed that, however, pulmonary thromboembolism (PTE) is a rare
complication of ABPA. We describe here the case of a young man with ABPA who was
admitted to hospital because of PTE after reccurent treatments for aspergillosis.
Case report. A 40-years old man was hospitalized in our department for “Acute pulmonary
thrombembolism at the level of big pulmonary vessels (pulmonary artery trunk) involving
acute pulmonary heart disease”. The patient was earlier diagnosed with Pulmonary
aspergilosis, for which he received a specific treatment 4-5 months ago with anti-fungic drugs-
Itroconazol, in Phthisiopulmonology Institute "Chiril Draganiuc". At the time of admission,
the patient presented the following accusations: moderate permanent dyspnea that does not
depend on physical effort, rare hemoptysis, weakness. No tuberculosis or asthma was reported,
neither other pathologies with immunosuppression. The patient had a 20-year smoking history
with 20-30 cigarettes per day. Vital signs in the emergency department were temperature
36,7oC, blood pressure 110/70 mm Hg, heart rate 82 bpm, respiratory rate 19/min, and oxygen
saturation 94% on room air. Auscultation showed a widespread audible expiratory wheeze on
both upper lungs and moist rales on both lower lungs. Breathing sound was low and the patient
had the symptom of expiratory dyspnea. Previous laboratory findings showed serum Apergillus
IgE levels of 1277 UI/mL (ULN<100.0) and positive A. fumigatus IgG =154mg/L (ULN<39).
Sputum culture was performed and A. fumigatus grew. The result of the D-dimer test was
435 μg/L (ULN 500 μg/L). However, chest angiography revealed filling defects in the main
pulmonary artery and both branches of the pulmonary artery, indicating the occurrence of PTE.
1 day later, the D-dimer tests had higher values and eosinophilia in addition. At EchoCG
examination: Pronounced dilatation of the right atrium and right ventricle. Severe pulmonary
hypertension (pulmonary artery = 28mm; pulmonary artery pressure = 81mmHg). Ejection
fraction = 56%. Congenital heart defect - ostium secundum=6mm.The patient was diagnosed
with PTE and received treatment of low molecular heparin (0.8 mL every 12 hours for 7 days)
and Warfarine (5 mg once per day). Symptoms gradually improved and the patient was
discharged with continued anticoagulant treatment.
Conclusions. 1. ABPA is a chronic disease with a relapsing remitting course, and the prognosis
can be improved by early diagnosis and treatment. 2. ABPA complicated with PTE is
extremely rare. 3. Consequently, much more attention should be paid to the ABPA patients
with the associated risk factors and/or those who are not responsive to antifungal treatment in
consideration of the life-threatening severity of PTE. 4. Since PTE is a life-threatening
disorder, clinicians should consider PTE in patients with ABPA, especially in patients who
suddenly had symptoms such as dyspnea or ineffective use of antifungal and hormonal drugs.
It is important to assess the additional risk of PTE in ABPA patients, and patients at high-risk
of PTE should receive prophylactic treatment, unless they have contraindications. |
en_US |